文献速递免疫规划传染病防控与疫情报告

二价mRNA疫苗预防≥65岁免疫功能正常成人COVID-19相关住院效果的早期估计——IVY网络,18个州,2022年9月8日至11月30日

Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2022-12-30

2022年9月8日至11月30日,IVY网络在18个州评估≥65岁免疫功能正常成人接种二价加强针后预防COVID-19相关住院的效果。与未接种者相比,二价加强针的疫苗有效性为84%;与仅接种≥2剂单价mRNA疫苗者相比,相对有效性为73%。

要点

  • ≥65岁免疫功能正常成人中,二价加强针较未接种者预防COVID-19住院的VE为84%。
  • 较仅接种≥2剂单价mRNA疫苗者,二价加强针的相对VE为73%。
  • 所有符合条件者,尤其是≥65岁成人,应接种二价加强针以最大化保护。

核心结论

  • 早期发现显示,二价加强针为老年人提供了预防COVID-19相关住院的强保护,并为既往仅接种单价mRNA疫苗者提供了额外保护。

研究设计与样本

  • IVY网络于2022年9月8日至11月30日在18个州评估≥65岁免疫功能正常成人接种二价加强针(在≥2剂单价mRNA疫苗后接种)预防COVID-19相关住院的效果。

主要发现

  • 与未接种者相比,在发病前≥7天接种二价加强针(中位数29天)预防COVID-19相关住院的VE为84%。
  • 与接种≥2剂单价mRNA疫苗者相比,二价加强针的相对VE为73%。

关键数值与推荐

  • 2022年9月1日,免疫实践咨询委员会推荐已完成至少基础COVID-19疫苗接种系列(含或不含单价加强针)≥2个月者接种二价COVID-19 mRNA加强针。

临床怎么用

  • 所有符合条件者,尤其是≥65岁成人,应接种二价加强针以最大化预防COVID-19住院的保护。
  • 还应考虑其他预防呼吸道疾病的策略,如在高COVID-19社区水平地区的室内公共场所戴口罩。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monovalent COVID-19 mRNA vaccines, designed against the ancestral strain of SARS-CoV-2, successfully reduced COVID-19-related morbidity and mortality in the United States and globally (1,2). However, vaccine effectiveness (VE) against COVID-19-associated hospitalization has declined over time, likely related to a combination of factors, including waning immunity and, with the emergence of the Omicron variant and its sublineages, immune evasion (3). To address these factors, on September 1, 2022, the Advisory Committee on Immunization Practices recommended a bivalent COVID-19 mRNA booster (bivalent booster) dose, developed against the spike protein from ancestral SARS-CoV-2 and Omicron BA.4/BA.5 sublineages, for persons who had completed at least a primary COVID-19 vaccination series (with or without monovalent booster doses) ≥2 months earlier (4). Data on the effectiveness of a bivalent booster dose against COVID-19 hospitalization in the United States are lacking, including among older adults, who are at highest risk for severe COVID-19-associated illness. During September 8-November 30, 2022, the Investigating Respiratory Viruses in the Acutely Ill (IVY) Network§ assessed effectiveness of a bivalent booster dose received after ≥2 doses of monovalent mRNA vaccine against COVID-19-associated hospitalization among immunocompetent adults aged ≥65 years. When compared with unvaccinated persons, VE of a bivalent booster dose received ≥7 days before illness onset (median = 29 days) against COVID-19-associated hospitalization was 84%. Compared with persons who received ≥2 monovalent-only mRNA vaccine doses, relative VE of a bivalent booster dose was 73%. These early findings show that a bivalent booster dose provided strong protection against COVID-19-associated hospitalization in older adults and additional protection among persons with previous monovalent-only mRNA vaccination. All eligible persons, especially adults aged ≥65 years, should receive a bivalent booster dose to maximize protection against COVID-19 hospitalization this winter season. Additional strategies to prevent respiratory illness, such as masking in indoor public spaces, should also be considered, especially in areas where COVID-19 community levels are high (4,5).

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Surie D, DeCuir J, Zhu Y, et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19-Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years - IVY Network, 18 States, September 8-November 30, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36580424. doi:10.15585/mmwr.mm715152e2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。